Anzeige
+++Hot Stock!: China kontrolliert Antimon, eines der hochgradigsten Projekte der Welt?! China kontrolliert Antimon, eines der hochgradigsten Projekte der Welt?!+++
EQS-News

NeuroOne(R) to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference March 17, 2026 at 1:20 p.m. Eastern Time 11.03.2026, 21:05 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
NeuroOne Medical Technologies Corporation 0,7401 USD +1,38 % Nasdaq

EQS-News: NeuroOne Medical Technologies / Key word(s): Financial
NeuroOne(R) to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference March 17, 2026 at 1:20 p.m. Eastern Time

11.03.2026 / 21:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


EDEN PRAIRIE, MINN. - March 11, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that the Company will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference virtually on March 17, 2026.

Dave Rosa, President & Chief Executive Officer, and Ron McClurg, Chief Financial Officer, will attend the Oppenheimer 36th Annual Healthcare MedTech & Services Conference virtually where they are scheduled to host one-on-one meetings with institutional investors. Mr. Rosa is also scheduled to deliver a Company presentation at 1:20 p.m. Eastern Time in Track 1 on Tuesday, March 17, 2026, and will provide commercialization updates and pipeline milestones for the OneRF® platform for treatment of the brain, pain, and advanced drug delivery.

Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Attendees: Dave Rosa, President & Chief Executive Officer, Ron McClurg, Chief Financial Officer
Format: Virtual 1x1 Meetings and Company Presentation
Presentation: Tuesday, March 17, 2026, at 1:20 p.m. Eastern Time in Track 1
Webcast Link: Here
Conference Website: Here

For more information on the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, or to schedule a meeting with management, please contact your conference representative or you may also email your request to NMTC@mzgroup.us or call Chris Tyson at (949) 491-8235.

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery and spinal cord stimulation programs. For more information, visit nmtc1.com.

Caution: Federal law restricts this device to sale by or on the order of a physician.

IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us


News Source: NeuroOne Medical Technologies


11.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: NeuroOne Medical Technologies
United States
ISIN: US64130M2098
EQS News ID: 2289984

 
End of News EQS News Service

2289984  11.03.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer